High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study

BACKGROUND: The IL-6R antibody tocilizumab has been proven effective in treating Takayasu arteritis (TA). However, some patients show silent vascular stenosis progression (VSP) despite treatment with tocilizumab. The aim of the study was to explore the related risk factors of VSP in patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Rongyi, Chen, Xiaojuan, Dai, Jinghua, Wang, Lingying, Ma, Xiaomin, Dai, Lili, Ma, Huiyong, Chen, Lindi, Jiang, Ying, Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394800/
https://www.ncbi.nlm.nih.gov/pubmed/37533103
http://dx.doi.org/10.1186/s13075-023-03106-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394800/
https://www.ncbi.nlm.nih.gov/pubmed/37533103
http://dx.doi.org/10.1186/s13075-023-03106-7

Ejemplares similares